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Abstract
Background: Platinum/fluoropyrimidine regimens are the backbone of first-line chemotherapy for advanced gastric
cancer (AGC). However response rates to first line chemotherapy range from 30 to 50% and disease progression
occurs after 4–6 cycles. The optimal duration of first-line therapy is still unknown and its continuation until disease
progression represents the standard. However this strategy is often associated with cumulative toxicity and rapid
development of drug resistance. Moreover, only about 40% of AGC pts. are eligible for second-line treatment.
Methods: This is a randomized, open-label, multicenter phase III trial. It aims at assessing whether switch
maintenance to ramucirumab plus paclitaxel will extend the progression-free survival (PFS) of subjects with
HER-2 negative AGC who have not progressed after 3 months of a first-line with a platinum/fluoropyrimidine
regimen (either FOLFOX4, mFOLFOX6 or XELOX). The primary endpoint is to compare Progression-Free
Survival (PFS) of patients in ARM A (switch maintenance to ramucirumab and placlitaxel) versus ARM B
(continuation of the same first-line therapy with oxaliplatin/fluoropyrimidine). Secondary endpoints are: overall
survival, time-to-treatment failure, overall response rate, duration of response, percentage of patients that will
receive a second line therapy according to arm treatment, safety, quality of life. Exploratory studies including
Next-Generation Sequencing (NGS) in archival tumor tissues are planned in order to identify potential biomarkers of
primary resistance and prognosis.
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Discussion: The ARMANI study estimates if patients treated with early swich with ramucirumab plus paclitaxel received
benefit when compared to those treated with continuation of first line therapy. The hypothesis is that the
early administration of an active, non-cross resistant second-line regimen such as ramucirumab plus paclitaxel
may prolong the time in which patients are progression-free, and consequently have a better quality of life.
Moreover, this strategy may rescue all those subjects that become ineligible for second-line therapy due to
the rapid deterioration of health status after the first disease progression.
Trial registration: ARMANI is registered at ClinicalTrials.gov (NCT02934464, October 17, 2016) and
EudraCT(2016–001783-12, April 202,016).
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Background
Gastric cancer (GC) is the 4th most common cancer
and the second leading cause of cancer-related death
with 700,000 deaths reported annually, with higher inci-
dence rates in Asia, Costa Rica, Peru, and Eastern Eur-
ope [1]. The five-year survival rate of gastroesophageal
adenocarcinoma is < 30% for all stages and < 4% for
metastatic disease [2, 3]. Systemic chemotherapy is the
standard treatment for HER2 negative, advanced gastric
or gastroesophageal junction (GEJ) cancers; first-line
chemotherapy generally consists of a fluroropyrimidine
and a platinum (cisplatin or oxaliplatin) combination
regimen [4].
The V325 Phase 3 trial showed that the addition of do-
cetaxel to cisplatin and 5FU combination improved pro-
gression free survival (PFS), overall response rate (ORR)
with a small improvement in median survival (median
9.2 months and 8.6 months, respectively, p = 0.02), with
increased toxicity [5]. Cunningham et al. in a large, mul-
ticenter, randomized Phase 3 study evaluated 4 regimens
in first line: epirubicin + oxaliplatin + 5-fluorouracil
(5-FU) [EOF], epirubicin + cisplatin + capecitabine
[ECX], epirubicin + cisplatin + 5-FU [ECF], epirubicin +
oxaliplatin + capecitabine [EOX]. No significant differ-
ences were observed in terms of response rate or PFS.
Overall survival time was significantly longer among pa-
tients receiving EOX versus ECF (9.9 months, 9.3
months, 9.9 months, and 11.2 months for ECF, EOF,
ECX, and EOX, respectively) [6]. Capecitabine was
shown to be non-inferior to fluorouracil in terms of
progression-free survival and overall survival [7]. A ran-
domized phase 3 study compared epirubicin, cisplatin
and capecitabine (ECX) with5-FU, l-leucovorin and iri-
notecan (FOLFIRI) as first line treatment in patients
with advanced gastric or GEJ cancers. Patients were
treated until disease progression or unacceptable tox-
icity. The results demonstrated no differences in re-
sponse rate, median progression-free survival (PFS), and
overall survival (OS) between the two treatments, except
for time to treatment failure (TTF) that was significantly
longer in FOLFIRI arm (median TTF: 4.24 vs. 5.1
months; p = 008). A second line therapy was adminis-
tered only in 39% of patients treated with FOLFIRI ver-
sus 48% of patients treated with ECX. Approximately
only 19% of patients received third line treatment [8].
In the past years two targeted therapies have been ap-
proved so far by the FDA in USA and EMA in EU for
advanced GC (AGC): Trastuzumab and Ramucirumab.
Trastuzumab is a monoclonal antibody targeting a
tumor molecular alteration, that is HER2 overexpres-
sion/amplification, found in 10–15% of AGC. It has been
shown to have survival benefit in combination with cis-
platin/fluoropyrimidine for HER2 positive GC [9]. On
the other hand, ramucirumab is a human IgG1 mono-
clonal antibody targeting Vascular Endothelial Growth
Factor Receptor 2 (VEGFR2), and it is the first biological
treatment given as a single drug that has survival bene-
fits in patients with HER2 negative AGC or GEJ adeno-
carcinoma progressing after first-line chemotherapy.
Ramucirumab was approved in many countries for the
treatment of AGC refractory to treatment with fluoro-
pyrimidines and platinum (with or without an anthracy-
cline).based on the positive results of two randomized,
double-blind, placebo-controlled, phase III studies. In
the REGARD trial, patients progressing after first-line
therapy with platinum/fluoropyrimidine regimens were
treated with ramucirumab versus placebo [10], while in
the RAINBOW trial they were given the combination of
ramucirumab plus paclitaxel versus placebo plus pacli-
taxel [11]. These trials reported a median OS (mOS) of
5.2 months vs 3.8 months (hazard ratio [HR] 0.776, 95%
CI 0.603–0.998; p = 0.047) and a mOS of 9.6 months vs
7.4 months (HR 0.807, 95% CI 0.678–0.962]; p = 0.017),
respectively [12]. Of note, treatment with ramucirumab
was associated with improved quality of life results and
longer time to clinical deterioration in both the RE-
GARD and the RAINBOW studies. As far as adverse
events (AEs) are concerned, the REGARD trial reported
similar AEs in the two treatment groups, with the
exception of a higher incidence of hypertension in the
ramucirumab arm. The combination of ramucirumab
and paclitaxel, in the RAINBOW trial, resulted in a
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higher incidence of some ≥ G3 adverse events (AEs),
such as neutropenia, hypertension and fatigue. Ramucir-
umab is now considered to be a standard second-line
therapy of AGC in many countries.
Additionally, the results of the phase III RAINFALL
study were recently published [13]. The objective of the
study was to evaluate the benefit, in term of PFS, of
ramucirumab in combination with fluoropyrimidine and
cisplatin as first line therapy as compared to fluoropyri-
midine and cisplatin alone in patients with AGC. The
primary endpoint was met, as there was a very modest
but statistically significant increase in median PFS for
ramucirumab plus chemotherapy versus chemotherapy
alone (5.7 vs. 5.4 months; HR 0.753, 95% CI [0.607,
0.935]; p = 0.0106). However, there was no difference in
mOS (11.2 vs. 10.7 months; HR 0.962, 95% CI [0.801,
1.156]; p = 0.6757) nor in overall response rate (41.1% vs.
36.4%; p = 0.17) or disease control rate (81.9% vs. 76.5%;
p = 0.095). Among randomized patients, only 50% of
patients were treated in second line. However the
post-progression treatment (ramucirumab as second line
therapy) contributed to jeopardize the survival advan-
tage. Based on these disappointing results, ramucirumab
will not be pursued for a first-line indication in GC.
In summary, platinum/fluoropyrimidine regimens rep-
resent the backbone of first-line chemotherapy for AGC;
the addition of a third chemotherapeutic agent was ei-
ther associated with an increase in toxicity (i.e, doce-
taxel), or with a not-demonstrated superiority when
compared to doublets [14]. Therefore, the use of triplet
regimens in the first-line treatment of gastric cancer pa-
tients is limited and not standard. Additionally, clinical
responses to first-line treatments range from 30% up to
50%, but disease progression occurs after a median of 4–
6 cycles of chemotherapy. Only about 40% of the poten-
tial trial population is eligible for second-line treatment,
whichever the first-line therapy is.
Continuation of fist-line chemotherapy until disease
progression or unacceptable toxicity is consistent with
observations in clinical practice, published international
guidelines and phase III clinical trials in AGC [5, 7, 15,
16] .There is currently no approved treatment as main-
tence therapy following first-line treatment for gastric
cancer. Since standard of care is not yet established in
this setting, best supportive care (BSC) or continuation
of fluoropyrimidine are accepted after a lead-in chemo-
therapy with platinum /fluoropyrimidine association.
Recently, switch maintenance for initial treatment of
AGC with immunotherapy has already been conducted
in the JAVELIN Gastric 100 study, which results are not
mature yet [17].
The ARMANI study is designed to define whether
switch maintenance with ramucirumab plus paclitaxel
will extend PFS of subjects affected by with HER-2
negative AGC who have not progressed after a first-line
platinum/fluoropyrimidine regimen, as compared to
continuation of first-line chemotherapy.
Methods
Aims
Primary objective of this study is to compare PFS of sub-
jects who receive switch maintenance therapy with
ramucirumab plus paclitaxel (arm A) following a
first-line chemotherapy doublet combination versus sub-
jects who receive continuation of first-line chemotherapy
until progressive disease,unacceptable toxicity, patient’s
withdrawal consent or death (arm B).
Secondary objectives of this trial are to evaluate OS,
time-to-treatment failure (TTF), overall response rate
(ORR) and duration of response (DOR) of patients
who receive switch maintenance (arm A) versus pa-
tients who receive continuation therapy (arm B). Add-
itionally, the study will compare the percentage of
patients that will receive a second line therapy ac-
cording to arm treatment and it will evaluate safety
(according to CTCAE v 4.03) and quality of life (pa-
tients reported outcomes [PRO]).
Trial design
The ARMANI trial is an open label, multicenter,
phase III randomized study. This is a superiority trial
evaluating ramucirumab plus paclitaxel, given as
switch maintenance (arm A), versus continuation of
first-line chemotherapy (arm B), given as per standard
clinical practice, in subjects with unresectable locally
advanced or metastatic HER-2 negative gastric or GEJ
cancer, without disease progression following 3
months of first-line doublet chemotherapy with fluor-
opyrimidine (either 5-FU or capecitabine) and oxali-
platin. Patients will be enrolled by their treating
investigators and assigned to a treatment arm by 1:1
central randomization. Before randomization the pa-
tients will be stratified by center; prior gastrectomy;
peritoneal carcinomatosis; site of origin. The planned
population of 280 patients will be randomized at 32
study centers in Italy (see Table 1). Investigator meet-
ings and monthly accrual updates will be held to en-
sure adequate enrollment. The study schema is
depicted in Fig. 1.
Study endpoints
The primary endpoint is PFS, defined as the time from
randomization to the first documentation of objective dis-
ease progression or death due to any cause, whichever oc-
curs first. Descriptive analysis of PFS will be carried out by
plotting Kaplan−Meier survival curves, and median sur-
vival will be estimated. As typically done for this type of
studies, superiority of the experimental treatment arm
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versus the control one will be established if the confidence
interval upper margin of PFS difference is inferior to 1.
An additional analysis will be conducted by mean of
the Cox proportional hazard regression model, in-
corporating information on recognized prognostic
factors so as to obtained an adjusted estimate of ex-
perimental treatment effect. Similar analyses will be
conducted on OS.
All efficacy analyses will be primarily based on the
intention-to-treat (ITT) population, and further verified
on the per-protocol population.
Secondary endpoints are:
– OS, defined as the time from the first day of treatment
to the date of death due to any cause. For patients still
alive at the time of analysis, the OS time will be
censored on the last date the patients were known to
be alive.
– Time-to-treatment failure (TTF), defined as the time
from the first day of treatment to the first occurrence
of progressive disease and/or withdrawal due to
adverse events, insufficient therapeutic response,
death, lost to follow-up, refusing treatment/being
unwilling to cooperate/withdrawing consent.
– Overall response rate (ORR), defined as the percentage
of patients achieving complete and partial responses
according to RECIST 1.1 criteria. Best overall response
is the best response recorded from the start of
treatment until disease progression. Complete and
partial responses have to be confirmed by two
evaluations of the disease.
– Duration of response (DOR), defined as the time
from the initial occurrence of documented CR or PR
(whichever occurs first) until documented disease
progression as determined by RECIST 1.1.
– The percentage of patients that will receive a second
line therapy according to arm treatment.
– Safety, assessed through summaries of adverse events
graded according to NCI CTCAE 4.03
Exploratory endpoints
As exploratory endpoints, potential biomarkers and their
correlation with outcome measures will be investigated
as follows: change in plasma biomarkers, such as circu-
lating cytokines, and their correlation with outcomes
(PFS, ORR, and OS); pharmacogenetic studies to find a
potential correlation between single nucleotide polymor-
phisms and ramucirumab-related toxicity and efficacy,
chemotherapy-related toxicity, drugs dose intensity and
outcomes (PFS, ORR, and OS); tissue biomarkers
present at baseline and investigated with next-generation
sequencing (NGS). Samples will be stored at Pathology
Department of Fondazione IRCCS Istituto Nazionale
Tumori.
Clinical setting
Patients affected by unresectable, locally advanced or
metastatic, HER-2 negative adenocarcinoma of the stom-
ach or GEJ can be evaluated for the study. To be consid-
ered eligible, patients must have received 3 months of
first-line chemotherapy with one of the fluoropyrimidines-
and oxaliplatin-based doublet combinations allowed, with
radiological evidence of clinical benefit (either
complete response/partial response/stable disease [CR/
PR/SD] by RECIST v1.1 criteria in case of measurable
disease, or absence of progressive disease in case of
non-measurable disease). Patients who had received
Table 1 Participating Centers
Principal Investigator Site Name
Maria Di Bartolomeo Istituto Tumori, Milano
Giovanni Luca Frassineti IRST, Meldola (FO)
Stefano Tamberi IRST, Ravenna
Davide Tassinari U.O. Ospedale degli Infermi, Rimini
Giorgio Scagliotti AOU San Luigi Gonzaga, Orbassano (TO)
Sara Lonardi IRCCS Istituto Oncologico Veneto, Padova
Andrea Bonetti Ospedale Mater Salutis, Legnago (VR)
Giovanni Gerardo Cardellino AOU, Udine
Rossana Berardi Ospedali Riuniti, Ancona
Alberto Zaniboni Fondazione Poliambulanza, Brescia
Mario Scartozzi AOU Cagliari, Cagliari
Lorenza Rimassa Humanitas Cancer Center, Rozzano (MI)
Alberto GianLuigi Luporini IRCCS Policlinico San Donato, Milano
Giampaolo Tortora Policlinico G.B. Rossi, Verona
Alessandro Bertolini Azienda Ospedaliera Sondrio
Gabriele Luppi AOU, Modena
Francesco Giuliani Istituto Oncologico, Bari
Samantha Di Donato H Nuovo, Prato
Evaristo Maiello Ospedale Casa Sollievo della Sofferenza,
San Giovanni Rotondo (FO)
Francesco Di Costanzo AOU Careggi, Firenze
Graziella Pinotti H di Circolo, Varese
Raffaella Longarini H San Gerardo, Monza
Saverio Cinieri H Perrino, Brindisi
Gianluca Tomasello H Cremona, Cremona
Hector Soto Parra P.O.G. Rodolico, Catania
Lorenzo Fornaro AOU Pisa
Sergio Bracarda AUSL Arezzo, Arezzo
Vincenzo Catalano H Riuniti Marche Nord, Pesaro
Libero Ciuffreda H Molinette, Torino
Claudio Verusio H Saronno, Saronno (VA)
Michele Basso Policlinico A. Gemelli, Roma
Ferdinando De Vita AOU L. Vanvitelli, Napoli
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adjuvant cisplatin/oxaliplatin plus fluoropyrimidine-
based doublet chemotherapy and had recurrence be-
yond 12 months from its completion are eligible.
Other main inclusion criteria are:
– Measurable and/or evaluable disease based on
RECIST v1.1
– ECOG PS 0–1
– Adequate hematologic, hepatic, renal and coagulation
function
– Available archival tumor tissue for exploratory
research
Main exclusion criteria are:
– HER2 positive status, or diagnosis of squamous cell
carcinoma.
– Unresolved toxicity greater than or equal to CTCAE
Grade 2 attributed to any prior therapies
– Any serious illness or medical condition(s) that
could be considered contraindications for any
study drugs
– Treatment with any of the following, within the
specified time frame, prior to study drug
administration:
A. major surgery within 28 days prior to
randomization, or central venous access device
placement within 7 days prior to randomization.
b. Any investigational agent including VEGF or
VEGFR-targeted agents within prior 4 weeks.
c. Extended field radiation within prior 4 weeks or
limited field radiation within prior 2 weeks.
Treatment
The acceptable first-line or lead-in chemotherapy for this
protocol will be a fluoropyrimidine and oxaliplatin-contain-
ing doublet (bi-weekly oxaliplatin and 5-FU [FOLFOX-4 or
mFOLFOX-6 regimen]; three-weekly oxaliplatin and cape-
citabine [XELOX regimen]). In the induction phase, treat-
ment must be continued for up to 4 three-weekly cycles or
6 bi-weekly cycles, or for up to a maximum of 12weeks.
Subjects with CR/PR/SD after oxaliplatin and
fluoropirimides-based regimen in case of measurable
disease, or without progressive disease in case of
non-measurable disease, will be randomized in 1:1 ratio
between the two treatment arms:
(Arm A) ramucirumab 8mg/kg on Days 1 and 15 of
every 28-day cycle; paclitaxel 80 mg/m2 on Days 1, 8,
and 15 of every 28-day cycle.
(Arm B): Continuation of the same induction regimen
(FOLFOX-4 or mFOLFOX-6 for up to 6 cycles, XELOX
for up to 4 cycles), followed by capecitabine or 5-FU
alone.
Those on arm A will receive ramucirumab plus pac-
litaxel until progressive disease, unacceptable toxicity,
informed consent withdrawal or patient’s death. In
case of permanent discontinuation of paclitaxel due
to unacceptable toxicity (particularly cumulative
grade > 2 neurotoxicity), treatment with single-agent
bi-weekly ramucirumab will be continued until pro-
gressive disease, unacceptable toxicity, informed con-
sent withdrawal or patient’s death. In case of
permanent discontinuation of ramucirumab due to
unacceptable drug-specific toxicity, treatment with
weekly paclitaxel will be continued until progressive
Fig. 1 Study design
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disease, unacceptable toxicity, informed consent with-
drawal or patient’s death.
Patients in arm B will receive continuation of the same
regimen used as lead-in chemotherapy with the same
dosage of the last cycle until progressive disease, un-
acceptable toxicity, informed consent withdrawal or pa-
tient’s death. Treatment will be further administered for
up to 6 bi-weekly cycles in the FOLFOX schedules or
for up to 4 three-weekly cycles in the XELOX schedule;
then, after a maximum of 24 weeks of treatment (includ-
ing both lead-in phase and post-randomization treat-
ment), single agent fluoropyrimidines (capecitabine or
5-FU) will be continued until progressive disease, un-
acceptable toxicity, informed consent withdrawal or pa-
tient’s death. In case of oxaliplatin-induced severe and
cumulative toxicity, prior to completion of 24-weeks in-
tensive treatment phase, single agent fluoropyrimidine
can be given as maintenance. Second-line treatment will
be at Investigator’s discretion.
Statistical design
This is a randomized, open-label, multicenter phase III
trial. We plan to enroll up to 280 patients, 140 in the
control group and 140 in the study group, over a
two-year period. The follow up period is estimated to be
of 1 year. The sample size is calculated on the basis of a
superiority hypothesis of median PFS with ramucirumab
plus a paclitaxel as compared to continuation of
first-line CT following the randomization after the in-
duction phase of 3 months. Taking into account a me-
dian PFS of 7 months observed in the REAL-2 trial, an
overall sample size of 280 subjects (140 in the control
group and 140 in the study group) achieves 90% power
to detect a probability of increase of median PFS after
the induction period from 4months in the control group
to 6 months in the experimental group, with a signifi-
cance level of 0.05 (2-sided). Equal 1:1 allocation ratio
by central randomization in the two trial arms is
planned, and the patient accrual pattern over time is
foreseen to be uniform. Intention-to-treat Population:
All patients that are included in the trial by signing the
informed consent and assigned a study patient number
(randomized patients). Per Protocol Population: Pa-
tients will be excluded from the per-protocol analysis
if: 1)they did not receive a minimum of 2 cycles of
treatment before undergoing the first radiological re-
assessment, or 2) there were severe violations of
protocol inclusion or exclusion criteria (for example:
absence of written informed consent, HER-2 positive
GC, progressive disease after the last dose of the
lead-in chemotherapy).
Demographic and baseline characteristics such as age,
sex, race, and baseline disease characteristics will be
summarized by treatment arm for the ITT population.
Descriptive baseline summaries of continuous data will
present mean, standard deviation, median, minimum,
and maximum. Descriptive summaries of discrete data
will present the category counts as frequencies and
percentages.
Descriptive analysis of PFS will be carried out by plot-
ting Kaplan−Meier survival curves, and median survival
will be estimated. As typically done for studies of this
type, superiority of experimental treatment toward con-
trol will be established in case of the confidence interval
upper margin of PFS difference will be inferior to 1. An
additional analysis will be conducted by mean of the
Cox proportional hazard regression model, incorporat-
ing information on recognized prognostic factors so as
to obtained an adjusted estimate of experimental treat-
ment effect. Similar analyses will be conducted on OS.
All efficacy analyses will be primarily based on the
ITT population, and further verified on the per-protocol
population.
The analysis of patients’ reported outcome (PRO-
assessed using the EORTC QLQ-C30, the EORTC
QLQ-OG25 and the EuroQol EQ-5D questionnaires)
will be performed according to the EORTC Scoring and
Reference Values Manual. All scores and subscales will
be assessed through descriptive summary statistics.
For PFS, patients without a date of disease progres-
sion will be analyzed as censored observations on the
date of last tumor assessment. If no post-baseline
tumor assessment is available, PFS will be censored at
day 1. For OS, patients who are not reported as being
died will be analyzed as censored observations on the
date when they were last known to be alive. If no
post-baseline data are available, OS will be censored
at day 1. Patients not receiving at least one dose of
study drug will be excluded from the analysis of
safety. Tables of adverse event incidence and individ-
ual incidence will be produced according to the pri-
mary system-organ class (SOC) and within the
category defined in the CTCAE v4.03. The summaries
will be overall (severity grades 1–5) and for grade ≥ 3
events. Multiple occurrences of the same event will
be counted once at the maximum severity. A comple-
mentary analysis of adverse events by severity of
event and by relationship to trial treatment will also
be performed. The actions taken in terms of treat-
ment discontinuation will be reported. A standard
safety analysis with tables and shift tables for labora-
tory data will be provided.
The Trial Office of Fondazione IRCCS Istituto Nazio-
nale dei Tumori will develop electronic case report form
(eCRF) specific for this study. The Sponsor Fondazione
IRCCS Istituto Nazionale dei Tumori will be responsible
for data management of this study, including quality
checking of the data.
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Discussion
The optimal duration of systemic first-line chemo-
therapy for metastatic gastric cancer is unknown. In
many trials, chemotherapy was given until progression
or limiting toxicity, whereas in other trials treatment
was stopped at a pre-defined time. Given the increas-
ing toxicity rate with a prolonged administration of
systemic chemotherapy, patients’ quality of life could
be negatively affected. Additionally, regardless the
strategy of treatment, the PFS does not seem to be
affected.
Given the positive results of both randomized trials
and reports from clinical experiences [10, 11, 18],
ramucirumab either alone or in combination with
paclitaxel has proved to be a safe and active option
for second line treatment in gastric cancer. Unfortu-
nately, RAINFALL study failed to prove a clinically
relevant benefit of a ramucirumab-based regimen in
the first-line setting, as compared to chemotherapy
doublets [19]. Nevertheless, the early administration
of an active, non-cross resistant treatment after the
first-line therapy, before disease progression occurs,
might prolong the benefit of first-line treatment and
could delay clinical deterioration [20–22]. Small phase
2 trials investigated the feasibility of sequential ther-
apy in AGC [20–22], and they showed the potential
of sequential therapy in order to prolong therapeutic
benefit of first-line, but with the price of cumulative
toxicities. Our hypothesis is that the early administra-
tion of a safe second-line regimen such as ramuciru-
mab plus paclitaxel may prolong progression-free
survival and consequently allow patients to experience
a better quality of life.
PFS was chosen as primary endpoint instead of OS be-
cause the latter could be influenced by the best second
line treatment available after trial for both arms and by
the percentage of patients that are in adequate clinical
condition for a second line therapy.
Many other maintenance studies, both for metastatic
colorectal and lung cancers, have, in fact, PFS as primary
endpoint, as it reflects the direct effect of the mainten-
ance therapy on delaying the disease progression and it
is not influenced by post progression treatments.
This topic is remarkably relevant in gastric cancer
patients, in which only 40% is usually eligible for
second-line treatment, independently of the first-line
therapy, due to the rapid deterioration of health status
after the first disease progression. The early administra-
tion of an active second-line treatment could overcome
this problem and it may rescue all those subjects that
become ineligible for such therapy.
Additionally, as exploratory endpoints, we will investi-
gate several potential efficacy and toxicity biomarkers
both in blood and tissue samples.
Therefore, the ARMANI study will help us at defining
whether switchmaintenance with ramucirumab plus pac-
litaxel is a better strategy then continuation of first-line
chemotherapy for HER-2 negative AGC who have not
progressed after first-line platinum/fluoropyrimidine
regimen.
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5-FU: 5-fluoruracil; AEs: adverse events; AGC: advanced gastric cancer;
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ECF: epirubicin + cisplatin + 5-FU; ECOG PS: Eastern Cooperative Oncology
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ECX: epirubicin + cisplatin + capecitabine; EMA: European Medicines Agency;
EOF: epirubicin + oxaliplatin + 5-fluorouracil (5-FU); EOX: epirubicin +
oxaliplatin + capecitabine; ESMO: European Society for Medical Oncology;
FDA: Food and Drug Administration; FOLFIRI: Folinic-acid, 5-fluorouracil, irino-
tecan; FOLFOX: Folinic-acid, 5-fluorouracil, Oxaliplatin; GEJ: gastroesophageal
junction cancers; HR: Hazard Ratio; NCI CTCAE: National Cancer Institute
Common Terminology Criteria for Adverse Events; NGS: Next-Generation
Sequencing; ORR: Overall Response Rate; OS: Overall Survival;
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